Abstract
Summary
We examined osteoporosis diagnosis/treatment in 2,187 community dwelling men age 50+. After five years in the study, 90% of men with fragility fractures remained undiagnosed and untreated for osteoporosis. The need to treat fragility fractures is well established in guidelines, and these numbers represent an important care gap.
Introduction
Whether physicians in the community are recognizing and appropriately treating osteoporosis and fragility fractures in men remains unknown. We examined the rate of diagnosis and treatment in community dwelling men participating in the Canadian Multicentre Osteoporosis Study (CaMos).
Methods
Between February 1996 and September 2002, 2,187 participants were recruited from nine sites across Canada and prospectively followed. Information on osteoporosis diagnosis, fractures, medications were collected annually by a detailed questionnaire. DXA examination of lumbar spine (L1-4) and hip were conducted at baseline and year five.
Results
Diagnosis and treatment in men with clinical fragility fractures was low: at baseline and year five only 2.3% and 10.3% of men with a clinical fracture reported an osteoporosis diagnosis, respectively. At year five, 90% of men with a clinical fragility fracture were untreated. Hip fractures were the most commonly treated (37.5% by year five). A diagnosis of osteoporosis resulted in greater treatment: 67% of participants with diagnosed osteoporosis were treated with a bisphosphonate and 87% were taking calcium and/or vitamin D (year five).
Conclusions
In this population-based study, both a diagnostic and therapeutic gap existed between knowledge and practice related to fragility fractures and osteoporosis in men aged ≥50 years.
Similar content being viewed by others
References
National Osteoporosis Foundation (2002) America’s bone health: the state of osteoporosis and bone health. National Osteoporosis Foundation, Washington, DC. USA
Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2:285–289
Pluijm SM, Tromp AM, Smit JH et al (2000) Consequences of vertebral deformities in older men and women. J Bone Miner Res 15:1564–1572
Burger H, Van Daele PL, Grashuis K et al (1997) Vertebral deformities and functional impairment in men and women. J Bone Miner Res 12:152–157
Jackson SA, Tenenhouse A, Robertson L (2000) Vertebral fracture definition from population-based data: preliminary results from the Canadian Multicenter Osteoporosis Study (CaMos). Osteoporos Int 11:680–687
Kanis JA, Johnell O, Oden A et al (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674
Melton LJ 3rd, Chrischilles EA, Cooper C et al (2005) How many women have osteoporosis? JBMR Anniversary Classic. JBMR, Volume 7, Number 9, 1992. J Bone Miner Res 20:886–892
Forsen L, Sogaard AJ, Meyer HE et al (1999) Survival after hip fracture: short- and long-term excess mortality according to age and gender. Osteoporos Int 10:73–78
Jiang HX, Majumdar SR, Dick DA et al (2005) Development and initial validation of a risk score for predicting in-hospital and 1-year mortality in patients with hip fractures. J Bone Miner Res 20:494–500
Hawkes WG, Wehren L, Orwig D et al (2006) Gender differences in functioning after hip fracture. J Gerontol A Biol Sci Med Sci 61:495–499
Osnes EK, Lofthus CM, Meyer HE et al (2004) Consequences of hip fracture on activities of daily life and residential needs. Osteoporos Int 15:567–574
Marottoli RA, Berkman LF, Leo-Summers L et al (1994) Predictors of mortality and institutionalization after hip fracture: the New Haven EPESE cohort. Established populations for epidemiologic studies of the elderly. Am J Public Health 84:1807–1812
Papaioannou A, Wiktorowicz M, Adachi JD et al (2000) Mortality, independence in living, and re-fracture, one year following hip fractures in Canadians. J Obstet Gynaecol Can 22:591–597
Elliot-Gibson V, Bogoch ER, Jamal SA et al (2004) Practice patterns in the diagnosis and treatment of osteoporosis after a fragility fracture: a systematic review. Osteoporos Int 15:767–778
Papaioannou A, Giangregorio L, Kvern B et al (2004) The osteoporosis care gap in Canada. BMC Musculoskelet Disord 5:11
Giangregorio L, Papaioannou A, Cranney A et al (2006) Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum 35:293–305
National Osteoporosis Foundation [homepage on the Internet] Washington, DC. USA. National Osteoporosis Foundation, c2003 [cited June 2006]. Physician’s Guide to Prevention and Treatment of Osteoporosis; [about 1 screen]. Available from: http://noforg/physguide/
(1996) Clinical practice guidelines for the diagnosis and management of osteoporosis. Scientific Advisory Board, Osteoporosis Society of Canada. CMAJ 155:1113–1133
Brown JP, Josse RG (2002) 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 167:S1–S34
Kanis JA, Johnell O, De Laet C et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382
Klotzbuecher CM, Ross PD, Landsman PB et al (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739
Phillipov G, Phillips PJ, Leach G et al (1998) Public perceptions and self-reported prevalence of osteoporosis in South Australia. Osteoporos Int 8:552–556
Juby AG, Davis P (2001) A prospective evaluation of the awareness, knowledge, risk factors and current treatment of osteoporosis in a cohort of elderly subjects. Osteoporos Int 12:617–622
Hajcsar EE, Hawker G, Bogoch ER (2000) Investigation and treatment of osteoporosis in patients with fragility fractures. CMAJ 163:819–822
Kreiger N, Tenenhouse A, Joseph L et al (2002) The Canadian Multicenter Osteoporosis Study (CaMos): background, rationale, methods. Can J Aging 18:376–387
Genant HK, Grampp S, Gluer CC et al (1994) Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 9:1503–1514
Tenenhouse A, Joseph L, Kreiger N et al (2000) Estimation of the prevalence of low bone density in Canadian women and men using a population-specific DXA reference standard: the Canadian Multicentre Osteoporosis Study (CaMos). Osteoporos Int 11:897–904
Sawka AM, Thabane L, Papaioannou A et al (2005) A systematic review of the effect of alendronate on bone mineral density in men. J Clin Densitom 8:7–13
Ringe JD, Faber H, Farahmand P et al (2006) Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427–431
Sawka AM, Papaioannou A, Adachi JD et al (2005) Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 6:39
Orwoll E, Ettinger M, Weiss S et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 343:604–610
Simonelli C, Killeen K, Mehle S et al (2002) Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons. Mayo Clin Proc 77:334–338
Jaglal SB, McIsaac WJ, Hawker G et al (2003) Information needs in the management of osteoporosis in family practice: an illustration of the failure of the current guideline implementation process. Osteoporos Int 14:672–676
Papaioannou A, Coker E, Kennedy CK et al (2004) A multi-faceted post fracture care model: the fracture? Think osteoporosis! Program. J Bone Miner Res 19:S318
Bogoch ER, Elliot-Gibson V, Beaton DE et al (2006) Effective initiation of osteoporosis diagnosis and treatment for patients with a fragility fracture in an orthopaedic environment. J Bone Joint Surg Am 88:25–34
Harrington JT, Barash HL, Day S et al (2005) Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthritis Rheum 53:198–204
Kmetic A, Joseph L, Berger C et al (2002) Multiple imputation to account for missing data in a survey: estimating the prevalence of osteoporosis. Epidemiology 13:437–444
Acknowledgements
The Canadian Multicentre Osteoporosis Study was funded by the Canadian Institutes of Health Research (CIHR), Merck Frosst Canada Ltd., Eli Lilly Canada Inc., Novartis Pharmaceuticals Inc., The Alliance: sanofi-aventis & Procter and Gamble Pharmaceuticals Canada Inc., The Dairy Farmers of Canada, The Arthritis Society. The authors wish to acknowledge the CaMos Research Group, for its role in implementing and overseeing the project. We thank Claudie Berger and Wei Zhou for data analysis and manuscript review, and Janet Pritchard for her assistance with editing and submitting the manuscript.
Role of the sponsor
The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Competing interests
Alexandra Papaioannou, MD, MSc
Consulting Role: Amgen, Eli Lilly, Merck Frosst, Novartis, Proctor & Gamble, sanofi aventis Clinical Trials: Eli Lilly, Merck, Novartis, Proctor & Gamble, sanofi-aventis,
Wojciech P. Olszynski, MD, PhD
Consulting Role: Abbott Laboratories, Merck Frosst, Amgen, Novartis, Aventis, Pfizer, Boehringer Ingelheim, Procter & Gamble, Eli Lilly, Sanofi-Synthelabo, Genzyme, Schering Canada, GlaxoSmithKline, Solvay Pharma, Hoffmann-LaRoche, Wyeth, Janssen-Ortho Inc./Ortho-Biotech
STEPHANIE KAISER, MD
Consulting Role: Eli Lilly, Proctor & Gamble /Aventis, Merck, Servier, Novartis, Astra Zeneca, Abbott Advisory boards: Eli Lilly, Novartis, Servier
David A. Hanley, MD
Advisory Boards: Merck, Proctor & Gamble, Eli Lilly, Novartis, NPS Pharmaceuticals, Paladin Clinical Trials: Merck, Proctor & Gamble, Eli Lilly, Novartis, NPS Pharmaceuticals, Pfizer, Amgen, Wyeth-Ayerst, Roche
Jonathan D. Adachi, MD
Consulting Role: Amgen; Astra Zeneca, Eli Lilly; GlaxoSmithKline; Merck Frosst; Novartis; Proctor & Gamble; Roche; Sanofi Aventis; Servier Clinical Trials: Eli Lilly; GlaxoSmithKline; Merck; Novartis; Pfizer; Proctor & Gamble; sanofi-aventis; Servier; Wyeth-Ayerst
David Goltzman, MD
Consulting Role: Lilly, Novartis, Merck, sanofi-aventis, Proctor & Gamble, Servier
Robert G. Josse, MD
Advisory boards, honoraria, research grants: Lilly, Proctor & Gamble/sanofi-aventis, Merck, Novartis, Servier, GlaxoSmithKline, Amgen
Jacques P. Brown, MD
Consulting Role: Eli Lilly, Novartis, Procter & Gamble, and Sanofi-Aventis
Jerilynn C. Prior MD, Courtney C. Kennedy MSc, George Ioannidis MSc, Yongjun Gao MSc, Anna M. Sawka MD, PhD, Nancy Kreiger PhD, Shawn Davison PhD, Laura Pickard MA: No competing interests to declare.
Rights and permissions
About this article
Cite this article
Papaioannou, A., Kennedy, C.C., Ioannidis, G. et al. The osteoporosis care gap in men with fragility fractures: the Canadian Multicentre Osteoporosis Study. Osteoporos Int 19, 581–587 (2008). https://doi.org/10.1007/s00198-007-0483-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-007-0483-0